A antibiotic that barely enters the bloodstream can still treat gut conditions

A antibiotic that barely enters the bloodstream can still treat gut conditions
Image: Intellect (generated)

In short: Rifaximin is an antibiotic that is poorly absorbed after swallowing, so most of it stays in the gut where it acts. That local action helps explain why it is used for traveler's diarrhea, irritable bowel syndrome and liver-related brain changes, and why resistance develops less readily than with many antibiotics.

Rifaximin belongs to the rifamycin family and is a semisynthetic broad-spectrum antibiotic, made by chemically modifying the natural antibiotic rifamycin. It was developed by Salix Pharmaceuticals and has been approved since 1987 in Italy, and has since been licensed in more than 30 countries. Its best-known use is treating travelers' diarrhea caused by E. coli in people aged twelve and over, though it does not work where the diarrhea is bloody or comes with fever.

It works by binding to the RNA polymerase enzyme in susceptible bacteria, which blocks a step in transcription and so halts the bacteria's ability to make the RNA they need. Because very little of the drug is absorbed from the gut, most of it remains where the infection is, which is why it is considered to have an excellent safety profile in the trials reported. Researchers also describe a reduction in gas-producing bacteria and a possible anti-inflammatory effect on the gut lining, and the drug has been found to raise levels of certain butyrate-making microbes, including Faecalibacterium prausnitzii, in animals and humans.

Its use for irritable bowel syndrome and hepatic encephalopathy, a condition in which toxins build up in the brain of people with liver disease, is more nuanced. For irritable bowel syndrome, the source says it relieves symptoms such as abdominal pain, bloating and stool consistency, but repeated courses may be needed. For hepatic encephalopathy, it appears to be at least as effective as lactulose and may act faster, although the source notes that high-quality evidence is lacking and that trials have largely been done alongside lactulose.

Caution is needed in several cases: people allergic to rifabutin, rifampin or rifapentine should avoid it, it may make some vaccines such as typhoid less effective, and it should be avoided in pregnancy and breastfeeding. Its patent status has also shaped access, with US generic entry delayed by a patent dispute settled in 2018, and the source reports that a similar drug, Aemcolo, was approved for traveler's diarrhea in the same year.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-rifaximin.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…